Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis. 1984

M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer

The influence of an 8-day therapy with rifampicin (600 mg daily) was studied on antipyrine plasma clearance and metabolite formation in seven patients with tuberculosis (age 18-79 years), who were also treated with isoniazid and pyrazinamide. After rifampicin treatment the elimination half-life of antipyrine had decreased in all patients from 12.9 +/- 5.0 to 8.8 +/- 2.0 h (P less than 0.05). Antipyrine clearance had increased from 2.2 +/- 0.9 to 2.9 +/- 0.7 l/h (P less than 0.05), while no change in apparent volume of distribution was observed. The increase in antipyrine clearance was primarily due to a selective increase in the rate of formation of norantipyrine by 80% from 6.9 +/- 3.4 to 12.4 +/- 3.4 ml/min. Rifampicin seems to induce preferentially the cytochrome P-450 (iso-) enzyme(s) involved in the demethylation of antipyrine to norantipyrine. Other pathways of antipyrine metabolism were hardly affected. This provides further evidence for the involvement of different iso-enzymes of the cytochrome P-450 system in antipyrine metabolism in man.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone

Related Publications

M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
November 1984, British journal of clinical pharmacology,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
January 1984, European journal of clinical pharmacology,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
August 1986, European journal of clinical investigation,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
April 1994, British journal of clinical pharmacology,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
February 2001, Digestive diseases and sciences,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
December 1985, British journal of clinical pharmacology,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
January 1984, European journal of clinical pharmacology,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
January 1975, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
August 1983, Xenobiotica; the fate of foreign compounds in biological systems,
M W Teunissen, and W Bakker, and J E Meerburg-Van der Torren, and D D Breimer
September 1983, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!